Thursday, January 27, 2011

Assignment of Drugs to treat CFS

On Jan. 26, the FDA's Office of New Drugs announced that all new applications for CFS treatments will be assigned to the Division of Pulmonary, Allergy and Rheumatology Products. This decision may help streamline review of products that were previously scattered to six different revew divisions. Here's the FDA announcement:

No comments: